(Q50580140)

English

Randomized trial of three different regimens for 24 weeks for re-treatment of chronic hepatitis C patients who failed to respond to interferon-alpha monotherapy in Taiwan.

scientific article published in December 2004

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

15 March 2018

http://europepmc.org/abstract/MED/15566510

Randomized trial of three different regimens for 24 weeks for re-treatment of chronic hepatitis C patients who failed to respond to interferon-alpha monotherapy in Taiwan. (English)

1 reference

Europe PubMed Central

PubMed publication ID

15 March 2018

http://europepmc.org/abstract/MED/15566510

chronic hepatitis C

1 reference

based on heuristic

inferred from title

author name string

Wan-Long Chuang

1

1 reference

Europe PubMed Central

PubMed publication ID

15 March 2018

http://europepmc.org/abstract/MED/15566510

Chia-Yen Dai

2

1 reference

Europe PubMed Central

PubMed publication ID

15 March 2018

http://europepmc.org/abstract/MED/15566510

Shinn-Cherng Chen

3

1 reference

Europe PubMed Central

PubMed publication ID

15 March 2018

http://europepmc.org/abstract/MED/15566510

Li-Po Lee

4

1 reference

Europe PubMed Central

PubMed publication ID

15 March 2018

http://europepmc.org/abstract/MED/15566510

Zu-Yau Lin

5

1 reference

Europe PubMed Central

PubMed publication ID

15 March 2018

http://europepmc.org/abstract/MED/15566510

Ming-Yuh Hsieh

6

1 reference

Europe PubMed Central

PubMed publication ID

15 March 2018

http://europepmc.org/abstract/MED/15566510

Liang-Yen Wang

7

1 reference

Europe PubMed Central

PubMed publication ID

15 March 2018

http://europepmc.org/abstract/MED/15566510

Ming-Lung Yu

8

1 reference

Europe PubMed Central

PubMed publication ID

15 March 2018

http://europepmc.org/abstract/MED/15566510

Wen-Yu Chang

9

1 reference

Europe PubMed Central

PubMed publication ID

15 March 2018

http://europepmc.org/abstract/MED/15566510

publication date

1 December 2004

1 reference

Europe PubMed Central

PubMed publication ID

15 March 2018

http://europepmc.org/abstract/MED/15566510

Liver International

1 reference

Europe PubMed Central

PubMed publication ID

15 March 2018

http://europepmc.org/abstract/MED/15566510

24

1 reference

Europe PubMed Central

PubMed publication ID

15 March 2018

http://europepmc.org/abstract/MED/15566510

6

1 reference

Europe PubMed Central

PubMed publication ID

15 March 2018

http://europepmc.org/abstract/MED/15566510

595-602

1 reference

Europe PubMed Central

PubMed publication ID

15 March 2018

http://europepmc.org/abstract/MED/15566510

Hepatitis C virus infection

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2004.0954.X

21 January 2018

Predictors of sustained response to alpha interferon therapy in chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2004.0954.X

21 January 2018

Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2004.0954.X

21 January 2018

Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (I

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2004.0954.X

21 January 2018

Possible association between serum GB virus C RNA level and disease activity in fulminant hepatitis type G.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2004.0954.X

21 January 2018

Better efficacy of a 12-month interferon alfa-2b retreatment in patients with chronic hepatitis C relapsing after a 6-month treatment: a multicenter, controlled, randomized trial. Le Groupe D'étude et De Traitement du Virus De L'hépatite C (Get.Vhc)

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2004.0954.X

21 January 2018

Therapy of hepatitis C: re-treatment with alpha interferon

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2004.0954.X

21 January 2018

Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. International Hepatitis Interventional Therapy Group

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2004.0954.X

21 January 2018

Retreatment for 24 vs 48 weeks with interferon-alpha2b plus ribavirin of chronic hepatitis C patients who relapsed or did not respond to interferon alone.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2004.0954.X

21 January 2018

A randomized, controlled trial to determine whether continued ribavirin monotherapy in hepatitis C virus-infected patients who responded to interferon-ribavirin combination therapy will enhance sustained virologic response

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2004.0954.X

21 January 2018

Interferon alpha-2B and ribavirin in combination for patients with chronic hepatitis C who failed to respond to, or relapsed after, interferon alpha therapy: a randomized trial.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2004.0954.X

21 January 2018

Sequential versus concomitant administration of ribavirin and interferon alfa-n3 in patients with chronic hepatitis C not responding to interferon alone: results of a randomized, controlled trial

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2004.0954.X

21 January 2018

Interferon and ribavirin vs interferon alone in the re-treatment of chronic hepatitis C previously nonresponsive to interferon: A meta-analysis of randomized trials.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2004.0954.X

21 January 2018

Interferon and ribavirin for patients with chronic hepatitis C who did not respond to previous interferon therapy: a meta-analysis of controlled and uncontrolled trials

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2004.0954.X

21 January 2018

Combination of interferon and ribavirin in chronic hepatitis C: re-treatment of nonresponders to interferon

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2004.0954.X

21 January 2018

Treatment of chronic hepatitis C in patients who failed interferon monotherapy: effects of higher doses of interferon and ribavirin combination therapy. The Virginia Cooperative Hepatitis Treatment Group

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2004.0954.X

21 January 2018

Combined treatment of relapse of chronic hepatitis C with high-dose alpha2b interferon plus ribavirin for 6 or 12 months.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2004.0954.X

21 January 2018

Comparative effects of different doses of ribavirin plus interferon-alpha2b for therapy of chronic hepatitis C: results of a controlled, randomized trial

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2004.0954.X

21 January 2018

A randomized trial of ribavirin and interferon-alpha vs. interferon-alpha alone in patients with chronic hepatitis C who were non-responders to a previous treatment. Multicenter Study Group under the coordination of the Necker Hospital, Paris, Franc

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2004.0954.X

21 January 2018

A randomized 4-arm multicenter study of interferon alfa-2b plus ribavirin in the treatment of patients with chronic hepatitis C relapsing after interferon monotherapy

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2004.0954.X

21 January 2018

Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2004.0954.X

21 January 2018

Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2004.0954.X

21 January 2018

Meta-analysis of interferon randomized trials in the treatment of viral hepatitis C: Effects of dose and duration

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2004.0954.X

21 January 2018

Meta-analysis of interferon randomized trials in the treatment of viral hepatitis C in naive patients: 1999 Update

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2004.0954.X

21 January 2018

Identifiers

10.1111/J.1478-3231.2004.0954.X

1 reference

Europe PubMed Central

PubMed publication ID

15 March 2018

http://europepmc.org/abstract/MED/15566510

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

15 March 2018

http://europepmc.org/abstract/MED/15566510

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q50580140&oldid=1540655467"